Metformin increases pathologic complete response rates in breast cancer patients with diabetes
Monday, June 2, 2008 - 12:28
in Health & Medicine
Metformin, the common first-line drug for type 2 diabetes, may be effective in increasing pathologic complete response rates in diabetic women with early stage breast cancer who took the drug during chemotherapy prior to having surgery, paving the way for further research of the drug as a potential cancer therapy, according to researchers at The University of Texas M. D. Anderson Cancer Center.
Read the whole article on Physorg
More from Physorg
Related
- Metformin increases pathologic complete response rates in breast cancer patients with diabetesMon, 2 Jun 2008, 13:29:02 EDT
- Study finds no relationship between PCR rate and race in women with breast cancerFri, 9 Oct 2009, 14:18:51 EDT
- M. D. Anderson study finds common diabetic therapy reduces risk of pancreatic cancerSat, 1 Aug 2009, 1:00:33 EDT
- Diabetes drug kills cancer stem cells in combination treatment in miceMon, 14 Sep 2009, 11:50:22 EDT
- M. D. Anderson study finds racial disparities in radiation therapy rates for breast cancerThu, 4 Sep 2008, 14:14:53 EDT